(Q49627711)

21 February 2018

title

Advancing psychiatric pharmacogenomics using drug development paradigms. (English)

1 reference

21 February 2018

1 reference

Ryan M Smith

1

1 reference

21 February 2018

publication date

4 October 2017

1 reference

21 February 2018

published in

Pharmacogenomics

1 reference

21 February 2018

volume

18

1 reference

21 February 2018

issue

15

1 reference

21 February 2018

page(s)

1459-1467

1 reference

21 February 2018

Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Predictors of clozapine discontinuation in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Pharmacogenomics in Psychiatric Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Psychiatric genetics: progress amid controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

The genetic basis of variability in drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2. Metabolism and elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Cytochrome P450-mediated drug metabolism in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

mRNA transcript diversity creates new opportunities for pharmacological intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

A Laminated Microfluidic Device for Comprehensive Preclinical Testing in the Drug ADME Process

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Stem cell culture and differentiation in microfluidic devices toward organ-on-a-chip

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Functional Coupling of Human Microphysiology Systems: Intestine, Liver, Kidney Proximal Tubule, Blood-Brain Barrier and Skeletal Muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Microphysiological Human Brain and Neural Systems-on-a-Chip: Potential Alternatives to Small Animal Models and Emerging Platforms for Drug Discovery and Personalized Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2017-0104

21 January 2018

Identifiers

DOI

10.2217/PGS-2017-0104

1 reference

21 February 2018

PubMed ID

28975860

1 reference

21 February 2018